PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system
Atherosclerosis is a primary precursor of cardiovascular disease (CVD), the leading cause of death worldwide. While proprotein convertase subtilisin/kexin 9 (PCSK9) contributes to CVD by degrading low-density lipoprotein receptors (LDLR) and altering lipid metabolism, PCSK9 also influences vascular...
Main Authors: | Jounghyun H. Lee, Kevin L. Shores, Jason J. Breithaupt, Caleb S. Lee, Daniella M. Fodera, Jennifer B. Kwon, Adarsh R. Ettyreddy, Kristin M. Myers, Benny J. Evison, Alexandra K. Suchowerska, Charles A. Gersbach, Kam W. Leong, George A. Truskey |
---|---|
Format: | Article |
Language: | English |
Published: |
AIP Publishing LLC
2023-12-01
|
Series: | APL Bioengineering |
Online Access: | http://dx.doi.org/10.1063/5.0167440 |
Similar Items
-
Tissue Chips and Microphysiological Systems for Disease Modeling and Drug Testing
by: Leslie Donoghue, et al.
Published: (2021-01-01) -
Light-triggered cardiac microphysiological model
by: V. Vurro, et al.
Published: (2023-06-01) -
A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
by: Alexandra K. Suchowerska, et al.
Published: (2022-11-01) -
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
by: Emily Punch, et al.
Published: (2022-02-01) -
Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
by: Yanan Wang, et al.
Published: (2023-02-01)